Janet H Cunningham

US Patent:

20020192188, Dec 19, 2002

Filed:

Aug 7, 2002

Appl. No.:

10/215164

Inventors:

Pierre Zoldhelyi - Bellaire TX, US
Janet Cunningham - Alameda CA, US
James Willerson - Houston TX, US

International Classification:

A61K048/00

US Classification:

424/093200, 514/044000

Abstract:

A recombinant adeno-associated virus is used to transduce the cells of a tissue graft ex vivo. More specifically, rAAV encoding a therapeutic protein is delivered to a vascular graft to prevent smooth muscle cell proliferation or thrombosis in the graft. The cells are transfected ex vivo with the recombinant virus carrying a gene known to inhibit the proliferation and migration of vascular smooth muscle cells, thrombosis, and atherosclerosis. The methods can be used for the treatment of restenosis, vascular thrombosis, balloon injury or other vascular pathology.

US Patent:

20040087028, May 6, 2004

Filed:

Sep 24, 2003

Appl. No.:

10/670449

Inventors:

Janet Cunningham - Alameda CA, US

Assignee:

Avigen Inc.

International Classification:

C12N015/861
C12N007/00

US Classification:

435/456000, 435/235100

Abstract:

The present invention relates to AAV expression vectors that allow the introduction and regulated expression of heterologous genes into mammalian tissues and cells. In certain embodiments, vectors of the present invention are ecdysone-inducible AAV expression vectors and AAV expression vectors encoding EcR and RXR. In this system, the heterologous gene is “turned off” until an inducer such as pon A is provided to the tissues or cells. The present invention also provides methods of using inducible AAV expression vectors.

US Patent:

20060099183, May 11, 2006

Filed:

Dec 15, 2005

Appl. No.:

11/300722

Inventors:

Pierre Zoldhelyi - Bellaire TX, US
Janet Cunningham - Alameda CA, US
James Willerson - Houston TX, US

International Classification:

A61K 48/00

US Classification:

424093200

Abstract:

A recombinant adeno-associated virus is used to transduce the cells of a tissue graft ex vivo. More specifically, rAAV encoding a therapeutic protein is delivered to a vascular graft to prevent smooth muscle cell proliferation or thrombosis in the graft. The cells are transfected ex vivo with the recombinant virus carrying a gene known to inhibit the proliferation and migration of vascular smooth muscle cells, thrombosis, and atherosclerosis. The methods can be used for the treatment of restenosis, vascular thrombosis, balloon injury or other vascular pathology.